Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...

The deal is expected to close in late Q2 2025, subject to Nevro shareholder and regulatory approval.Globus Medical also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP ...

周二，Truist Securities调整了对Globus Medical（NYSE:GMED）的展望，将目标价从90.00美元下调至82.00美元，同时维持对该公司股票的持有评级。该股目前交易价格为72.14美元，年初至今下跌12.78%，尽管 InvestingPro 数据显示公司保持着3.17的优秀财务健康评分。此次调整反映了公司最近关于季度收入季节性预期的沟通，显示其将回归疫情前的模式。

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement ...

Stifel重申买入评级和94.00美元的目标价，反映了对Globus Medical并购后指引和预期财务表现的审慎评估。该分析为投资者提供了一个框架，用于衡量这家医疗器械公司在未来几年实现每股收益增长目标所需的努力。凭借2.54的健康流动比率和适度的债务水平，GMED似乎已做好执行并购战略的准备。

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

Following the consummation of the Nevro Corp. acquisition, which we expect to close late in the second quarter of 2025, Globus Medical anticipates 2025 net sales of $2.8 billion to $2.9 billion ...